Search research articles
Contact Us
Filters
Showing results (21-30 of 44) with videos related to
Page
of 5
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 21, 2014
Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial
Laurent Cotte, Joséphine Braun, Caroline Lascoux-Combe, et al.
Digestive Diseases and Sciences
|
April 19, 2020
Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France
Denis Ouzan, Dominique Larrey, Dominique Guyader, et al.
Journal of Hepatology
|
June 7, 2014
Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection
Melissa E Laird, Amira Mohsen, Darragh Duffy, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
February 9, 2017
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme
Christophe Hézode, Pascal Lebray, Victor De Ledinghen, et al.
Journal of Hepatology
|
December 3, 2014
Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial
Thierry Thévenot, Christophe Bureau, Frédéric Oberti, et al.
The Lancet. Gastroenterology & Hepatology
|
April 14, 2017
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial
Marc Bourlière, Pascaline Rabiega, Nathalie Ganne-Carrie, et al.
Clinics and Research in Hepatology and Gastroenterology
|
June 30, 2020
Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort
Anais Vallet-Pichard, Jean-Michel Correas, Celine Dorival, et al.
Alimentary Pharmacology & Therapeutics
|
March 25, 2021
Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis
Pierre-Antoine Soret, Laurent Lam, Fabrice Carrat, et al.
European Journal of Gastroenterology & Hepatology
|
April 29, 2024
Hepatitis B Delta: assessment of the knowledge and practices of hepato-gastroenterologists practicing in non-academic settings in France
Jean-François D Cadranel, Honoré T Zougmoré, Jean-René Ngele Efole, et al.
Journal of Hepatology
|
July 13, 2025
Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trial
Thierry Thévenot, Laure Elkrief, Christophe Bureau, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 44) with videos related to
Sort By:
Page
of 5
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 21, 2014
Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial
Laurent Cotte, Joséphine Braun, Caroline Lascoux-Combe, et al.
Digestive Diseases and Sciences
|
April 19, 2020
Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France
Denis Ouzan, Dominique Larrey, Dominique Guyader, et al.
Journal of Hepatology
|
June 7, 2014
Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection
Melissa E Laird, Amira Mohsen, Darragh Duffy, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
February 9, 2017
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme
Christophe Hézode, Pascal Lebray, Victor De Ledinghen, et al.
Journal of Hepatology
|
December 3, 2014
Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial
Thierry Thévenot, Christophe Bureau, Frédéric Oberti, et al.
The Lancet. Gastroenterology & Hepatology
|
April 14, 2017
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial
Marc Bourlière, Pascaline Rabiega, Nathalie Ganne-Carrie, et al.
Clinics and Research in Hepatology and Gastroenterology
|
June 30, 2020
Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort
Anais Vallet-Pichard, Jean-Michel Correas, Celine Dorival, et al.
Alimentary Pharmacology & Therapeutics
|
March 25, 2021
Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis
Pierre-Antoine Soret, Laurent Lam, Fabrice Carrat, et al.
European Journal of Gastroenterology & Hepatology
|
April 29, 2024
Hepatitis B Delta: assessment of the knowledge and practices of hepato-gastroenterologists practicing in non-academic settings in France
Jean-François D Cadranel, Honoré T Zougmoré, Jean-René Ngele Efole, et al.
Journal of Hepatology
|
July 13, 2025
Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trial
Thierry Thévenot, Laure Elkrief, Christophe Bureau, et al.
Page
of 5